Clinical and genetic modifiers of long-term survival in heart failure.

ABSTRACT:

Objectives

This study sought to identify genetic modifiers of beta-blocker response and long-term survival in heart failure (HF).

Background

Differences in beta-blocker treatment effect between Caucasians and African Americans with HF have been reported.

Methods

This was a prospective cohort study of 2,460 patients (711 African American, 1,749 Caucasian) enrolled between 1999 and 2007; 2,039 patients (81.7%) were treated with a beta-blocker. Each was genotyped for beta1-adrenergic receptor (ADRB1) Arg389>Gly and G-protein receptor kinase 5 (GRK5) Gln41>Leu polymorphisms, which are more prevalent among African Americans than Caucasians. The primary end point was survival time from HF onset.

Results

There were 765 deaths during follow-up (median 46 months). beta-

SUBMITTER: Cresci S 

PROVIDER: S-EPMC2749467 | biostudies-literature | 2009 Jul

REPOSITORIES: biostudies-literature